Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca - LARVOL DELTA

Incidence and Severity of Interstitial Lung Disease Associated With Antibody-Drug Conjugates in NSCLC and SCLC: A Meta-Analysis (IASLC-WCLC 2025) - "In NSCLC, the highest pooled incidence of any-grade ILD was seen with patritumab deruxtecan (23%) and trastuzumab deruxtecan (22%), followed by datopotamab deruxtecan (9%), telisotuzumab vedotin (7%), and sacituzumab govitecan (1%)...Treatment discontinuation due to ILD in NSCLC was highest with telisotuzumab vedotin combined with erlotinib (36%), followed by trastuzumab deruxtecan (9%) and patritumab deruxtecan (7%)...In SCLC, any-grade ILD incidence was 8% with rovalpituzumab tesirine, with no reported grade ≥3 ILD events...HER2/HER3-targeted, deruxtecan-containing ADCs demonstrated the highest ILD rates, while other ADCs such as sacituzumab govitecan had minimal reported toxicity. These findings highlight the need for agent-specific ILD monitoring and support the consideration of ADC design, including target and payload, when evaluating pulmonary safety and guiding clinical decision-making."

Retrospective data • Interstitial Lung Disease • Lung Cancer • Non Small Cell Lung Cancer • Pulmonary Disease • Respiratory Diseases • Small Cell Lung Cancer • Solid Tumor • ERBB3 • HER-2

Daiichi Sankyo Presents…Updates Across ADC Portfolio (Daiichi Sankyo Press Release) - "Data updates at WCLC include an oral presentation featuring a retrospective analysis of the intracranial efficacy of DATROWAY (datopotamab deruxtecan) or docetaxel in patients with non-small cell lung cancer (NSCLC) and baseline brain metastases in the TROPION-Lung01 phase 3 trial (0A10.01), and a poster presentation of the final results of the DESTINY-Lung05 phase 2 trial (P2.10.12) of ENHERTU (trastuzumab deruxtecan) in patients from China with previously treated HER2 mutant NSCLC."

Clinical data • Non Small Cell Lung Cancer

A randomized Phase 3 study of first-line (1L) trastuzumab deruxtecan (T-DXd) with rilvegostomig or pembrolizumab in patients with HER2-expressing, mismatch repair-proficient (pMMR), primary advanced or recurrent endometrial cancer (EC): DESTINY-Endometrial01/GOG-3098/ENGOT-EN24 (ESMO 2025) - No abstract available

Clinical • Metastases • Mismatch repair • P3 data • pMMR • Endometrial Cancer • Oncology • Solid Tumor • HER-2

Real-world outcomes of trastuzumab deruxtecan in patients with HER2-mutant metastatic non-small cell lung cancer: a retrospective study (ESMO 2025) - No abstract available

Metastases • Real-world • Real-world evidence • Retrospective data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • HER-2

Construction of an Efficacy Prediction Model for T-DXd Treatment of HER2-Positive and HER2-Negative Breast Cancer Based on Hematological Indicators: A Multicenter Real-World Study (ESMO 2025) - No abstract available

Clinical • Real-world • Real-world evidence • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Real-world efficacy and safety of trastuzumab deruxtecan in HER2-positive and HER2-low metastatic breast cancer: Evidence from a Chinese population (ESMO 2025) - No abstract available

Clinical • Metastases • Real-world • Real-world effectiveness • Real-world evidence • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

The SURVIVE HERoes study: Targeting molecular relapse in breast cancer. A secondary adjuvant intervention study of trastuzumab deruxtecan versus SOC treatment in patients with HER2 positive or HER2 low early breast cancer and ctDNA positivity after primary therapy. (ESMO 2025) - No abstract available

Circulating tumor DNA • Clinical • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

EXTEND: Neoadjuvant Trastuzumab Deruxtecan (T-DXd) versus Standard Treatment for Medium-risk human epidermal growth factor receptor 2 (HER2)–positive Early Breast Cancer (ESMO 2025) - No abstract available

Clinical • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Impact of Skeletal Muscle Mass on Trastuzumab Deruxtecan (T-DXd) Toxicity in Solid Tumors (ESMO 2025) - No abstract available

Oncology • Solid Tumor

Real-World Clinical Outcomes of Trastuzumab Deruxtecan–Induced Interstitial Lung Disease: Experience from a Tertiary Cancer Center in the Middle East (ESMO 2025) - No abstract available

Clinical • Clinical data • Real-world • Real-world evidence • Oncology

Risk of hepatitis B virus reactivation (HBVr) in patients (pts) with past or resolved HBV or inactive chronic HBV infection treated with trastuzumab deruxtecan (T-DXd) in DESTINY-Gastric06 (DG-06) (ESMO 2025) - No abstract available

Clinical • Oncology

Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+ gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA) who received prior anti-HER2 treatment (Tx) other than / in addition to trastuzumab in DESTINY-Gastric06 (DG-06) (ESMO 2025) - No abstract available

Clinical • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor

Trastuzumab deruxtecan (T-DXd) vs ramucirumab (RAM) plus paclitaxel (PTX) in second-line (2L) treatment of patients (pts) with HER2+ unresectable/metastatic gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): Additional data from DESTINY-Gastric04 (DG-04) (ESMO 2025) - No abstract available

Clinical • Metastases • Esophageal Cancer • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor • HER-2

Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) Part 1 final analysis (ESMO 2025) - No abstract available

Clinical • Pan tumor • Oncology • Solid Tumor • HER-2

Phase I, dose-escalation study evaluating safety & efficacy of trastuzumab deruxtecan (T-DXd) in combination with ATR inhibitor (AZD6738, ceralasertib) in advanced solid tumors with HER2 expression (DASH) (ESMO 2025) - No abstract available

Clinical • Combination therapy • Metastases • Oncology • Solid Tumor • HER-2

Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic colorectal cancer (mCRC): final analysis of DESTINY-CRC02, a randomized, phase 2 trial (ESMO 2025) - No abstract available

Clinical • Metastases • P2 data • Colorectal Cancer • Oncology • Solid Tumor • HER-2

Real-world Safety and Efficacy Profiles of Trastuzumab-Deruxtecan in Patients with Advanced Breast Cancer (ESMO 2025) - No abstract available

Clinical • Metastases • Real-world • Real-world evidence • Breast Cancer • Oncology • Solid Tumor

Quantification of total trastuzumab (TTM) concentrations in blood samples from patients treated with trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-Dxd) (ESMO 2025) - No abstract available

Clinical • Oncology

Retrospective analysis of molecular resistance biomarkers to trastuzumab deruxtecan (T-DXd) in metastatic breast cancer (mBC) (ESMO 2025) - No abstract available

Biomarker • Metastases • Retrospective data • Breast Cancer • Oncology • Solid Tumor

The effectiveness of post-trastuzumab deruxtecan (T-DXd) treatment regimens and the incidence of recurrent interstitial lung disease (ILD) in patients (pts) with HER2+ metastatic breast cancer (mBC) who discontinued T-DXd due to ILD (ESMO 2025) - No abstract available

Clinical • Metastases • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Final real-world safety and effectiveness results of REALITY-01 study: trastuzumab deruxtecan (T-DXd) in patients received ≥2 prior treatment lines for HER2+ metastatic or unresectable (m/u) breast cancer (BC) (ESMO 2025) - No abstract available

Clinical • Metastases • Real-world • Real-world evidence • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Characterizing Patterns of Failure on Trastuzumab-Deruxtecan (T-DXd) among Patients with HER2 Low Metastatic Breast Cancer (ASTRO 2025) - No abstract available

Clinical • Metastases • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Trastuzumab deruxtecan (T-DXd) in pretreated patients (pts) with HER2-expressing solid tumors: exploratory biomarker analysis of DESTINY-PanTumor02 (DP-02) Part 1 (ESMO 2025) - No abstract available

Biomarker • Clinical • Pan tumor • Oncology • Solid Tumor • HER-2

DESTINY-Breast11: neoadjuvant trastuzumab deruxtecan alone (T-DXd) or followed by paclitaxel + trastuzumab + pertuzumab (T-DXd-THP) vs SOC for high-risk HER2+ early breast cancer (eBC) (ESMO 2025) - No abstract available

Clinical • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

HER2 and urothelial carcinoma: current understanding and future directions. (PubMed, Nat Rev Urol) - "Trastuzumab deruxtecan, a novel anti-HER2 ADC, has received FDA tumour-agnostic approval for unresectable or metastatic HER2+ solid tumours, including urothelial carcinoma, after prior therapies. Interactions between HER2 protein and putative biomarkers such as EGFR, NECTIN4, PDL1 and FGFR3 genomic alterations might influence therapeutic outcomes, offering opportunities for improved patient selection and innovative combination strategies."

IO biomarker • Journal • Review • Oncology • Solid Tumor • Urothelial Cancer • FGFR3 • HER-2 • NECTIN4 • PD-L1